Symbols / ORGO
ORGO Chart
About
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications. In addition, the company develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 514.63M |
| Enterprise Value | 619.37M | Income | -9.22M | Sales | 465.22M |
| Book/sh | 2.01 | Cash/sh | 0.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 869 | IPO | — |
| P/E | — | Forward P/E | 23.85 | PEG | — |
| P/S | 1.11 | P/B | 2.02 | P/C | — |
| EV/EBITDA | 31.67 | EV/Sales | 1.33 | Quick Ratio | 2.58 |
| Current Ratio | 3.32 | Debt/Eq | 10.57 | LT Debt/Eq | — |
| EPS (ttm) | -0.08 | EPS next Y | 0.17 | EPS Growth | 22.20% |
| Revenue Growth | 31.00% | Earnings | 2026-02-26 | ROA | 0.18% |
| ROE | 0.30% | ROIC | — | Gross Margin | 74.50% |
| Oper. Margin | 14.69% | Profit Margin | 0.22% | Shs Outstand | 126.91M |
| Shs Float | 56.93M | Short Float | 29.86% | Short Ratio | 16.30 |
| Short Interest | — | 52W High | 7.08 | 52W Low | 2.61 |
| Beta | 1.40 | Avg Volume | 1.04M | Volume | 109.09K |
| Target Price | $8.50 | Recom | None | Prev Close | $4.03 |
| Price | $4.05 | Change | 0.62% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.50
Mean price target
2. Current target
$4.08
Latest analyst target
3. DCF / Fair value
$-7.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.08
Low
$8.00
High
$9.00
Mean
$8.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-26 | reit | BTIG | Buy → Buy | $9 |
| 2025-12-15 | reit | BTIG | Buy → Buy | $9 |
| 2025-11-20 | main | BTIG | Buy → Buy | $9 |
| 2025-09-26 | reit | BTIG | Buy → Buy | $7 |
| 2025-08-08 | main | Cantor Fitzgerald | Overweight → Overweight | $9 |
| 2025-07-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $7 |
| 2025-03-05 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $6 |
| 2024-06-28 | init | Lake Street | — → Buy | $5 |
| 2024-03-01 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2024-02-07 | init | Cantor Fitzgerald | — → Overweight | $5 |
| 2023-12-27 | main | BTIG | Buy → Buy | $6 |
| 2023-11-14 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $4 |
| 2023-08-11 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $3 |
| 2023-08-10 | main | BTIG | Buy → Buy | $4 |
| 2023-06-15 | init | Morgan Stanley | — → Equal-Weight | $5 |
| 2023-05-24 | up | BTIG | Neutral → Buy | $10 |
| 2022-11-10 | down | BTIG | Buy → Neutral | — |
| 2021-11-10 | main | SVB Leerink | — → Outperform | $20 |
| 2021-08-10 | main | Credit Suisse | — → Outperform | $25 |
| 2021-05-11 | main | SVB Leerink | — → Outperform | $26 |
- Organogenesis Names Patrick McGuire Chief Accounting Officer - The Globe and Mail ue, 24 Feb 2026 08
- Equity grant gives Organogenesis (ORGO) director 48,828 RSUs vesting 2027 - Stock Titan Fri, 20 Feb 2026 22
- $ORGO stock is up 30% today. Here's what we see in our data. - Quiver Quantitative Fri, 07 Nov 2025 08
- Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring An 89% Potential Upside - DirectorsTalk Interviews Fri, 31 Oct 2025 07
- Organogenesis Holdings (NASDAQ:ORGO) pulls back 8.4% this week, but still delivers shareholders solid 26% CAGR over 3 years - Yahoo Finance Sun, 23 Nov 2025 08
- Organogenesis stock soars after FDA meeting clears path for ReNu BLA - Investing.com Mon, 15 Dec 2025 08
- The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Revenues Yet As Shares Tumble 28% - simplywall.st Sat, 17 Jan 2026 08
- Biggest stock movers Tuesday: RILY, CPAC, GUTS, RC, VITL and more - Seeking Alpha ue, 16 Dec 2025 08
- $ORGO stock is up 7% today. Here's what we see in our data. - Quiver Quantitative ue, 16 Dec 2025 08
- Organogenesis (Nasdaq: ORGO) to file BLA for ReNu knee OA pain by Dec. 2025 - Stock Titan Mon, 15 Dec 2025 08
- Organogenesis Holdings Inc. (ORGO) Stock Analysis: A 94.65% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews Fri, 24 Oct 2025 07
- Have Organogenesis Holdings Insiders Been Selling Stock? - simplywall.st Sat, 29 Nov 2025 08
- Earnings call transcript: Organogenesis Q3 2025 revenue beats forecasts, stock dips - Investing.com hu, 06 Nov 2025 08
- $ORGO stock is down 10% today. Here's what we see in our data. - Quiver Quantitative Fri, 26 Dec 2025 08
- Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring A 58.73% Potential Upside - DirectorsTalk Interviews Fri, 12 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 259549 | — | — | Stock Award(Grant) at price 0.00 per share. | BILBO PATRICK | Chief Operating Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 282705 | — | — | Stock Award(Grant) at price 0.00 per share. | GROW BRIAN | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 51843 | — | — | Stock Award(Grant) at price 0.00 per share. | MONTECALVO ANTONIO S | Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 48828 | — | — | Stock Award(Grant) at price 0.00 per share. | KORFIN MICHELE ILENE | Director | — | 2026-02-18 00:00:00 | D |
| 4 | 48828 | — | — | Stock Award(Grant) at price 0.00 per share. | DURAIBABU PRATHYUSHA | Director | — | 2026-02-18 00:00:00 | D |
| 5 | 238914 | — | — | Stock Award(Grant) at price 0.00 per share. | FRANCISCO DAVID | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 6 | 48828 | — | — | Stock Award(Grant) at price 0.00 per share. | DRISCOLL MICHAEL JOSEPH | Director | — | 2026-02-18 00:00:00 | D |
| 7 | 48828 | — | — | Stock Award(Grant) at price 0.00 per share. | QUINTERO GILBERTO | Director | — | 2026-02-18 00:00:00 | D |
| 8 | 110040 | — | — | Stock Award(Grant) at price 0.00 per share. | CAVORSI ROBERT | Officer | — | 2026-02-18 00:00:00 | D |
| 9 | 48828 | — | — | Stock Award(Grant) at price 0.00 per share. | LUSTIG GARRETT | Director | — | 2026-02-18 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.79M | 0.00 | 0.00 | -508.41K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.23 | 0.27 |
| NormalizedEBITDA | 38.56M | 27.95M | 33.02M | 88.88M |
| TotalUnusualItems | -22.80M | 0.00 | 0.00 | -1.88M |
| TotalUnusualItemsExcludingGoodwill | -22.80M | 0.00 | 0.00 | -1.88M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 861.00K | 4.95M | 15.53M | 94.20M |
| ReconciledDepreciation | 17.03M | 15.37M | 10.73M | 16.68M |
| ReconciledCostOfRevenue | 115.74M | 106.48M | 105.02M | 114.20M |
| EBITDA | 15.76M | 27.95M | 33.02M | 87.00M |
| EBIT | -1.26M | 12.58M | 22.29M | 70.32M |
| NetInterestIncome | -1.54M | -2.19M | -2.01M | -7.24M |
| InterestExpense | 1.54M | 2.19M | 2.01M | 7.24M |
| NormalizedIncome | 18.87M | 4.95M | 15.53M | 95.58M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 861.00K | 4.95M | 15.53M | 94.20M |
| TotalExpenses | 460.52M | 420.62M | 428.59M | 395.14M |
| TotalOperatingIncomeAsReported | -1.28M | 12.53M | 22.30M | 72.22M |
| DilutedAverageShares | 131.67M | 132.75M | 132.38M | 133.66M |
| BasicAverageShares | 131.67M | 131.23M | 130.07M | 128.33M |
| DilutedEPS | -0.01 | 0.04 | 0.12 | 0.71 |
| BasicEPS | -0.01 | 0.04 | 0.12 | 0.74 |
| DilutedNIAvailtoComStockholders | -937.00K | 4.95M | 15.53M | 94.20M |
| NetIncomeCommonStockholders | -937.00K | 4.95M | 15.53M | 94.20M |
| OtherunderPreferredStockDividend | 412.00K | 0.00 | 0.00 | 0.00 |
| PreferredStockDividends | 1.39M | |||
| NetIncome | 861.00K | 4.95M | 15.53M | 94.20M |
| NetIncomeIncludingNoncontrollingInterests | 861.00K | 4.95M | 15.53M | 94.20M |
| NetIncomeContinuousOperations | 861.00K | 4.95M | 15.53M | 94.20M |
| TaxProvision | -3.67M | 5.45M | 4.75M | -31.12M |
| PretaxIncome | -2.81M | 10.39M | 20.28M | 63.09M |
| OtherIncomeExpense | -22.78M | 57.00K | -13.00K | -1.90M |
| OtherNonOperatingIncomeExpenses | 20.00K | 57.00K | -13.00K | -13.00K |
| SpecialIncomeCharges | -22.80M | 0.00 | 0.00 | -1.88M |
| OtherSpecialCharges | 1.88M | |||
| WriteOff | 3.96M | 0.00 | 0.00 | |
| ImpairmentOfCapitalAssets | 18.84M | 0.00 | 0.00 | |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | ||
| NetNonOperatingInterestIncomeExpense | -1.54M | -2.19M | -2.01M | -7.24M |
| InterestExpenseNonOperating | 1.54M | 2.19M | 2.01M | 7.24M |
| OperatingIncome | 21.52M | 12.53M | 22.30M | 72.22M |
| OperatingExpense | 344.78M | 314.13M | 323.57M | 280.94M |
| ResearchAndDevelopment | 50.27M | 44.38M | 39.76M | 30.74M |
| SellingGeneralAndAdministration | 294.51M | 269.75M | 283.81M | 250.20M |
| GrossProfit | 366.30M | 326.66M | 345.87M | 353.16M |
| CostOfRevenue | 115.74M | 106.48M | 105.02M | 114.20M |
| TotalRevenue | 482.04M | 433.14M | 450.89M | 467.36M |
| OperatingRevenue | 482.04M | 433.14M | 450.89M | 467.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 728.55K | 728.55K | 728.55K | 728.55K |
| OrdinarySharesNumber | 125.73M | 131.32M | 130.92M | 128.68M |
| ShareIssued | 126.46M | 132.04M | 131.65M | 129.41M |
| TotalDebt | 43.31M | 119.35M | 123.79M | 132.30M |
| TangibleBookValue | 221.66M | 234.02M | 216.11M | 186.89M |
| InvestedCapital | 262.90M | 344.89M | 336.44M | 314.76M |
| WorkingCapital | 208.46M | 144.53M | 147.59M | 144.27M |
| NetTangibleAssets | 344.08M | 234.02M | 216.11M | 186.89M |
| CapitalLeaseObligations | 43.31M | 53.12M | 53.02M | 58.88M |
| CommonStockEquity | 262.90M | 278.66M | 265.67M | 241.34M |
| PreferredStockEquity | 122.42M | |||
| TotalCapitalization | 385.32M | 339.41M | 331.90M | 312.10M |
| TotalEquityGrossMinorityInterest | 385.32M | 278.66M | 265.67M | 241.34M |
| StockholdersEquity | 385.32M | 278.66M | 265.67M | 241.34M |
| RetainedEarnings | -40.11M | -40.97M | -45.30M | -60.83M |
| AdditionalPaidInCapital | 302.99M | 319.62M | 310.96M | 302.15M |
| CapitalStock | 122.43M | 13.00K | 13.00K | 13.00K |
| CommonStock | 13.00K | 13.00K | 13.00K | 13.00K |
| PreferredStock | 122.42M | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 112.57M | 181.36M | 183.69M | 201.92M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.09M | 100.85M | 108.67M | 119.22M |
| OtherNonCurrentLiabilities | 894.00K | 1.21M | 1.12M | 1.56M |
| NonCurrentDeferredLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 34.20M | 99.64M | 107.55M | 117.66M |
| LongTermCapitalLeaseObligation | 34.20M | 38.90M | 41.31M | 46.89M |
| LongTermDebt | 60.74M | 66.23M | 70.77M | |
| CurrentLiabilities | 77.48M | 80.51M | 75.02M | 82.70M |
| OtherCurrentLiabilities | 1.45M | 1.09M | 926.00K | 1.14M |
| CurrentDeferredLiabilities | 0.00 | 1.44M | ||
| CurrentDebtAndCapitalLeaseObligation | 9.11M | 19.71M | 16.25M | 14.64M |
| CurrentCapitalLeaseObligation | 9.11M | 14.22M | 11.71M | 11.98M |
| CurrentDebt | 5.49M | 4.54M | 2.66M | |
| OtherCurrentBorrowings | 5.49M | 4.54M | 2.66M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 23.84M | 18.29M | 17.11M | 26.86M |
| PayablesAndAccruedExpenses | 43.08M | 41.42M | 40.74M | 38.62M |
| CurrentAccruedExpenses | 9.88M | 7.90M | 5.78M | 8.12M |
| Payables | 33.20M | 33.52M | 34.95M | 30.50M |
| TotalTaxPayable | 4.29M | 2.80M | 2.62M | 1.16M |
| AccountsPayable | 28.91M | 30.72M | 32.33M | 29.34M |
| TotalAssets | 497.89M | 460.02M | 449.36M | 443.26M |
| TotalNonCurrentAssets | 211.94M | 234.98M | 226.75M | 216.28M |
| OtherNonCurrentAssets | 5.00M | 5.99M | 1.52M | 1.54M |
| NonCurrentDeferredAssets | 39.46M | 28.00M | 30.01M | 31.99M |
| NonCurrentDeferredTaxesAssets | 39.46M | 28.00M | 30.01M | 31.99M |
| GoodwillAndOtherIntangibleAssets | 41.24M | 44.64M | 49.56M | 54.45M |
| OtherIntangibleAssets | 12.47M | 15.87M | 20.79M | 25.67M |
| Goodwill | 28.77M | 28.77M | 28.77M | 28.77M |
| NetPPE | 126.24M | 156.35M | 145.66M | 128.30M |
| AccumulatedDepreciation | -72.95M | -73.19M | -62.80M | -57.73M |
| GrossPPE | 199.19M | 229.53M | 208.45M | 186.03M |
| Leases | 63.34M | 60.82M | 37.61M | 30.53M |
| ConstructionInProgress | 21.89M | 59.07M | 65.56M | 47.46M |
| OtherProperties | 37.11M | 40.12M | 43.19M | 49.14M |
| MachineryFurnitureEquipment | 63.25M | 64.58M | 57.15M | 53.96M |
| BuildingsAndImprovements | 13.60M | 4.94M | 4.94M | 4.94M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 285.94M | 225.04M | 222.61M | 226.98M |
| OtherCurrentAssets | 5.09M | 5.12M | 4.29M | 112.00K |
| RestrictedCash | 580.00K | 498.00K | 812.00K | 599.00K |
| PrepaidAssets | 8.62M | 5.34M | 795.00K | 4.86M |
| Inventory | 26.22M | 28.25M | 24.78M | 25.02M |
| FinishedGoods | 12.04M | 14.46M | 11.48M | 15.01M |
| WorkInProcess | 923.00K | 810.00K | 1.02M | 991.00K |
| RawMaterials | 13.25M | 12.99M | 12.28M | 9.02M |
| Receivables | 109.86M | 82.00M | 89.45M | 82.46M |
| AccountsReceivable | 109.86M | 82.00M | 89.45M | 82.46M |
| AllowanceForDoubtfulAccountsReceivable | -9.58M | -6.86M | -6.36M | -5.15M |
| GrossAccountsReceivable | 119.44M | 88.86M | 95.81M | 87.61M |
| CashCashEquivalentsAndShortTermInvestments | 135.57M | 103.84M | 102.48M | 113.93M |
| CashAndCashEquivalents | 135.57M | 103.84M | 102.48M | 113.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 4.18M | 6.55M | -9.04M | 30.76M |
| RepurchaseOfCapitalStock | -25.48M | 0.00 | 0.00 | 0.00 |
| RepaymentOfDebt | -67.64M | -5.17M | -3.01M | -75.19M |
| IssuanceOfDebt | 0.00 | 0.00 | 73.17M | |
| IssuanceOfCapitalStock | 120.69M | 0.00 | 0.00 | 0.00 |
| CapitalExpenditure | -10.03M | -24.36M | -33.90M | -31.22M |
| InterestPaidSupplementalData | 4.97M | 5.44M | 2.65M | 5.79M |
| IncomeTaxPaidSupplementalData | 6.96M | 3.05M | 1.20M | 607.00K |
| EndCashPosition | 136.15M | 104.34M | 103.29M | 114.53M |
| BeginningCashPosition | 104.34M | 103.29M | 114.53M | 84.81M |
| ChangesInCash | 31.81M | 1.05M | -11.24M | 29.72M |
| FinancingCashFlow | 27.64M | -5.50M | -2.20M | -1.04M |
| CashFlowFromContinuingFinancingActivities | 27.64M | -5.50M | -2.20M | -1.04M |
| NetOtherFinancingCharges | -1.18M | -332.00K | -1.26M | -1.22M |
| ProceedsFromStockOptionExercised | 1.25M | 0.00 | 2.07M | 2.20M |
| NetPreferredStockIssuance | 120.69M | 0.00 | 0.00 | |
| PreferredStockIssuance | 120.69M | 0.00 | 0.00 | |
| NetCommonStockIssuance | -25.48M | 0.00 | 0.00 | 0.00 |
| CommonStockPayments | -25.48M | 0.00 | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | -67.64M | -5.17M | -3.01M | -2.01M |
| NetShortTermDebtIssuance | -10.00M | |||
| NetLongTermDebtIssuance | -67.64M | -5.17M | -3.01M | -2.01M |
| LongTermDebtPayments | -67.64M | -5.17M | -3.01M | -75.19M |
| LongTermDebtIssuance | 0.00 | 0.00 | 73.17M | |
| InvestingCashFlow | -10.03M | -24.36M | -33.90M | -31.22M |
| CashFlowFromContinuingInvestingActivities | -10.03M | -24.36M | -33.90M | -31.22M |
| NetBusinessPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfBusiness | 0.00 | 0.00 | ||
| NetIntangiblesPurchaseAndSale | 0.00 | |||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | -10.03M | -24.36M | -33.90M | -31.22M |
| PurchaseOfPPE | -10.03M | -24.36M | -33.90M | -31.22M |
| OperatingCashFlow | 14.21M | 30.92M | 24.86M | 61.98M |
| CashFlowFromContinuingOperatingActivities | 14.21M | 30.92M | 24.86M | 61.98M |
| ChangeInWorkingCapital | -48.89M | -18.07M | -34.08M | -37.01M |
| ChangeInOtherWorkingCapital | -14.07M | -8.44M | -7.01M | -6.16M |
| ChangeInOtherCurrentLiabilities | -1.06M | 91.00K | 72.00K | -6.07M |
| ChangeInPayablesAndAccruedExpense | 6.79M | 3.03M | -8.59M | 13.20M |
| ChangeInAccruedExpense | 9.16M | 3.14M | -11.85M | 9.35M |
| ChangeInPayable | -2.37M | -108.00K | 3.26M | 3.85M |
| ChangeInAccountPayable | -2.37M | -108.00K | 3.26M | 3.85M |
| ChangeInPrepaidAssets | -2.55M | -10.12M | -378.00K | -34.00K |
| ChangeInInventory | -6.20M | -8.18M | -9.41M | -9.30M |
| ChangeInReceivables | -31.80M | 5.54M | -8.77M | -28.65M |
| ChangesInAccountReceivables | -31.80M | 5.54M | -8.77M | -28.65M |
| OtherNonCashItems | 8.91M | 8.06M | 10.58M | 9.93M |
| StockBasedCompensation | 10.58M | 9.00M | 6.55M | 3.86M |
| ProvisionandWriteOffofAssets | 3.94M | 1.30M | 1.78M | 3.00M |
| AssetImpairmentCharge | 31.15M | 8.08M | 7.30M | |
| DeferredTax | -10.72M | 2.01M | 1.98M | -31.98M |
| DeferredIncomeTax | -10.72M | 2.01M | 1.98M | -31.98M |
| DepreciationAmortizationDepletion | 17.03M | 15.37M | 10.73M | 16.68M |
| DepreciationAndAmortization | 17.03M | 15.37M | 10.73M | 16.68M |
| AmortizationCashFlow | 3.40M | 4.92M | 4.88M | 4.95M |
| AmortizationOfIntangibles | 3.40M | 4.92M | 4.88M | 4.95M |
| Depreciation | 13.62M | 10.45M | 5.84M | 11.73M |
| OperatingGainsLosses | 1.35M | 235.00K | 4.48M | 3.29M |
| GainLossOnSaleOfPPE | 1.14M | 235.00K | 4.48M | 1.41M |
| NetIncomeFromContinuingOperations | 861.00K | 4.95M | 15.53M | 94.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ORGO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|